Arbutus Biopharma Corporation (ABUS) CEO William Collier on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/03/22
Arbutus Reports Fourth Quarter and Year End 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/03/22
Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against ModernaGlobeNewsWire • 02/28/22
Genevant Sciences and Arbutus Biopharma File Patent Infringement Lawsuit Against ModernaGlobeNewsWire • 02/28/22
Arbutus to Report Fourth Quarter and Year End 2021 Financial Results and Provide Corporate UpdateGlobeNewsWire • 02/17/22
Antios Therapeutics and Arbutus Biopharma Announce First Patient Dosed in Phase 2a Combination Trial of ATI-2173, AB-729 and Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B Virus InfectionGlobeNewsWire • 12/14/21
Arbutus and Qilu Pharmaceutical Enter into an Exclusive Licensing Agreement and Strategic Partnership to Develop and Commercialize AB-729 in mainland China, Hong Kong, Macau and TaiwanGlobeNewsWire • 12/13/21
Arbutus Biopharma, X-Chem and Proteros biostructures Achieve First Milestone Under COVID-19 Discovery Research and License AgreementGlobeNewsWire • 12/07/21
Implied Volatility Surging for Arbutus Biopharma (ABUS) Stock OptionsZacks Investment Research • 12/03/21